The application of Flow cytometery in the detection of minimal residual disease in acute lymphoblastic leukemia

杨涛,乔振华,王宏伟,朱镭,张丽

DOI: https://doi.org/10.3969/j.issn.1007-6611.2003.01.025

2003-01-01

Abstract:Objective To approach the clinical significance of MRD using flow cytometery for detecting minimal residual disease(MRD)in acute lymphoblastic leukemia. Methods Thirty three patients with newly diagnosed ALL received remission induction chemotherapy for 4～6 weeks.Once completeremission was attained,the patients received consolidation therapy Bone marrow aspirates were collected after induction therapy and during weeks 12,24 and 36 of continuation therapy Cells with leukemia associated immunophenotypes were investigatedby flow cytometery,as immunologic target of MRD. Results At the beginningof disease lympho linge immunophenotype expressed in bone marrow of 33 patients,whileafter induction therapy and during weeks 12,24 and 36 of continuation therapy,the detectable rates of patients with MRD were 42 4%,31 3%,13 8% and 12 5%,respectively In different groups(based on age,sex,WBC counts,My expression,Ph chromosome and CNSL)the difference of detectable rates had no statistical significance MRD positive and WBC counts more than 50×10 9/L were the risk factors of ALL relapse( P 0 10) Conclusion ALL assotiated immunophynotype can be used as a target for detecting MRD in ALL.MRD may be an independent predictor risk of relapse.